

Précis:

Patients with metastatic melanoma who are HIV and Hepatitis B negative will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine, and then will be treated by the adoptive transfer of lymphocytes that are reactive with antigens on their tumors and are retrovirally transduced with a gene encoding IL-2. This study will evaluate the potential therapeutic role and toxicity of this treatment and the survival of the transferred cells.